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ABSTRACT 
 
The immune system plays a role in many different functions in our body, and disease is no 
exception. Cancer is one of the biggest challenges of the twenty first century and vast efforts 
have been made to understand this disease. Since the 1900s, we have evidence based that the 
immune system participates in cancer progression, but it was only some decades ago that we 
started to investigate it extensively. Currently, we know that the tumor microenvironment is 
infiltrated by different immune cells and depending on space and time they can participate in 
tumor initiation, promotion, progression and metastasis. Moreover, it has been shown that 
certain immune cell can influence tumor resistance to therapy. So far, most of the studies 
have been directed towards understanding tumor infiltrating T cells. However, in this thesis I 
focused on the interplay between different immune cells including B cells, T cells, Natural 
killer cells, macrophages and the tumor cells. Further from this research, we found potential 
predictive biomarkers associated with the checkpoint therapies, such as anti-CTLA-4, anti-
PD-1 and anti-PD-L1. 
 
This thesis can be divided into two major studies investigating two immune cell types 
infiltrating the tumor, B cells (Paper I and II) and macrophages (Paper III and IV).  More 
specifically, Paper I touches upon the role of B cells infiltrating two types of tumors, 
melanoma and breast cancer, studied in mouse models. Here, we could detect the presence of 
a heterogeneous B cell population that could be further divided by its surface CD5 
expression. These subpopulations were phenotypically and functionally distinct. In particular, 
CD5+ TIBs were found to have an activated phenotype and were able to secrete 
proinflammatory cytokines, which were induced by the tumor milieu. Additionally, we 
identified a similar B cell subpopulation in human breast cancer highlighting the importance 
of this finding. Paper II focused on the B cell responses towards melanoma when treated 
with immune checkpoint therapies anti-PD-1 or anti-PD-L1. This study showed an 
augmented IgG response against the tumor mice treated with checkpoint antibodies.  More 
importantly, it revealed significant differences in IgG subclasses depending on the checkpoint 
treatment given.  
 
In the second part of the thesis, paper III identifies MARCO, a scavenger receptor, as a 
novel marker for immunosuppressive TAMs subset present in three different mouse models, 
namely melanoma, mammary carcinoma and colon cancer. Monoclonal antibody against 
MARCO was found to successfully decrease the tumor growth and metastasis, while re-
polarizing this subpopulation of TAMs to have an anti-tumor phenotype. Moreover, we could 
observe an enhanced effect of anti-CTLA-4 treatment when combined with anti-MARCO.  
Finally, MARCO proved to be expressed in human metastatic melanoma and in an aggressive 
breast cancer subtype. Thus, targeting MARCO could potentially be a combinatory treatment 
for these cancer types. Paper IV further provides evidence on MARCO expression in a 
  
distinct subset of immunosuppressive TAMs, but now in human non-small cell lung cancer. 
Moreover, this study uncovered the strategical localization of MARCO positive macrophages 
at the tumor-stroma border. This creates an immunosuppressive barrier that could be 
potentially targeted with anti-MARCO.   
 
In summary, this thesis contributes to our overall understanding of the tumor 
microenvironment, specifically of B cells and macrophages. It gives us new possible targets 
and approaches for cancer therapy as well as potential predictive biomarkers. 
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1 INTRODUCTION 
  
1.1 BRIEF OVERVIEW OF THE IMMUNE SYSTEM 
 
The immune system´s main physiological function is to provide host defense against invading 
pathogens, such as virus, bacteria and fungi. It is comprised by a complex network of 
immune cells, organs and specialized molecules, which work together to prevent or eradicate 
potential threats and protect us from disease. This is possible due to unique capacity of the 
immune cells to discriminate between self- and non-self-molecules [1]. Deriving from 
hematopoietic stem cells precursors in the bone marrow through a process called 
hematopoiesis, the immune cells can commit to either to lymphoid or myeloid lineage.  While 
the lymphoid lineage gives rise to B cells, T cells , Natural Killer (NK) cells and innate 
lymphoid cells (ILC), the myeloid progenitors develop into granulocytes (basophils, 
eosinophils and neutrophils) and monocytes (later differentiating into macrophages and 
dendritic cells (DCs) [1]. These different types of immune cells participate in and have 
defined functions during an effector response. Classically, the immune response can be 
divided into two branches, the innate and the adaptive immune system. They diverge mainly 
in the timing and duration of the response, but also in the immune cells involved and 
specificity [2]. More importantly, they differ in the mechanisms through which they 
recognize antigens.  
The innate or “natural” immune system can be found in all multicellular organisms, being 
phylogenetically an older defense system. The pathogen recognition is therefore based on 
receptors encoded in the germline[3]. These receptors are called pattern recognition receptors 
(PRRs) and are able to identify structures shared by pathogens and not present on normal 
cells, named pathogen-associated molecular patterns (PAMPs) [1]. Examples of PPRs are for 
instance the toll-like receptor (TLR), which can bind to a wide range of molecules, including 
lipopolysaccharides (LPS), bacterial DNA and viral RNA. Additionally, they can also 
recognize endogenous damage-associated molecular patterns (DAMPs), which are released in 
damaged or necrotic cells [1]. The innate immune system is characterized by the ability to 
mount a fast effector response when encountering a pathogen for the first time. It occurs 
within minutes or hours of infection and therefore, is responsible for the first line of host 
defense. The innate immune system is constituted by different defensive barriers. First, 
anatomical (e.g. skin and musical membranes) and chemical barriers (e.g. low pH and 
antimicrobial peptides) protect the organism from most pathogens and when breached, 
internal barriers such as the complement system, phagocytic cells and inflammation come 
into play [2]. Macrophages and neutrophils are phagocytic cells that have a distinct ability to 
engulf microbes via PPRs. Besides these immune cells, NK cells, DCs and ILCs also 
participate in the effector function of innate immunity. In particular, DCs have the important 
function of antigen-presentation to T cells through the major histocompatibility complex 
(MHC), bridging the innate with adaptive immune system [1]. Likewise, inflammation has a 
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vital role in establishing an effector immune response. It is initiated by cells present in the 
damaged/infected tissue, for example macrophages, DCs and mast cells, which are able to 
release chemical factors responsible for the inflammatory response. Two other hallmarks of 
the innate immune system are the absence of antigen specificity and immunological memory. 
However, new studies have started to challenge the later concept by the discovery of 
memory-like NK cells in mice [4][5][6], which we presently name “trained immunity”[7]. 
On other hand, the adaptive immune system is a more specific response against pathogens. It 
is additionally a slower immune response, peaking only days after the immune recognition of 
the pathogen by the innate immune system. The adaptive immune effector function is 
mediated by B and T cells, two immune cells of lymphoid origin [1]. They are characterized 
by the expression of specialized receptors named B cell receptor (BCR) and T cell receptor 
(TCR), which undergo gene rearrangements (somatic recombination) during development 
[1]. This results in a wide diversity of antigen binding capacity of these receptors, which is an 
import hallmark of adaptive immunity. Moreover, both receptors differ in what they can bind. 
Whereas the BCR can bind directly to free antigen, taking into consideration for instance its 
conformational structure, the TCR can only bind to peptides presented on MHC molecules on 
the surface of antigen-presenting cells (APCs). In an ongoing response, T and B cells get 
activated upon antigen recognition and can undergo clonal selection, to ultimately eradicate 
the threat. Adaptive immunity is characterized by immunological memory, allowing faster 
responses towards a second encounter of the pathogen and thus, conferring to the host a 
lifelong protection [1]. 
In general, the immune system plays a central role in pathogen protection, but it is also 
involved in clearance of dead cells and initiation of tissue repair. However, when improperly 
regulated contributes to disease initiation and progression.    
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1.2 B CELLS 
 
In all vertebrates, the adaptive immune system is fundamentally organized by T and B cells. 
The separation between these two cell types was first described by Max Cooper and Robert 
Good, in 1965[8]. In chicken models, they discovered that B cells were developed in the 
bursa of Fabricius (equivalent to bone marrow in humans and mice) and the T cells in the 
thymus and more importantly, that both had different functions in adaptive immunity[8][9]. T 
cells were responsible for a delayed-type hypersensitivity response (later, T cell mediated 
immunity), while the B cells were accountable for the production of antibodies (humoral 
immunity). Since then, B cells have been studied and found to be a heterogeneous population 
capable of not only antibody production, but also act as APCs and as cytokine producers [10]. 
During the last years, B cells have come forward as important players in autoimmunity 
diseases and cancer malignancies. In this chapter, I will focus on the major subsets of B cell 
populations and their effector functions. 
 
1.2.1 B cell subsets 
 
Continuously produced throughout life, B cells leave the bone marrow, where they assemble 
their B cell receptor and enter circulation as transitional B cells. These cells have a BCR 
(specifically IgM) capable of recognizing specific antigenic epitopes and as described by 
Carsetti et al, can be subdivided into two groups, transitional type 1 (T1) and transitional type 
2 (T2) B cells [11]. T1 are characterized by their surface expression of IgM and upon further 
differentiation, they gain increased IgD expression through alternative splicing and become 
T2 B cells [12]. As transitional B cells have the ability to go to the periphery, they migrate to 
the spleen to become mature B cells.   
The mature lineages of B cells can be divided in two: B1 and B2 cells [13][14]. B2 cells 
originate from the bone marrow and can be further divided into follicular B cells (FoB) and 
marginal zone B cells (MZB). FoBs are the most predominant B cell subpopulation in the 
spleen and lymph nodes. They are circulating cells and as the name indicates, they home 
mainly to B cell follicles of secondary lymphoid organs, in close proximity to T cell zones 
[15]. Functionally, they are better suited to respond to protein antigens, in a T cell-dependent 
manner. Once activated FoBs and T cells meet in the T-B border, germinal center (GC) B 
cells are formed, differentiating finally, into antibody producing plasma cells [15][16]. Most 
of FoBs exhibit high levels of IgD, low levels of IgM and are positive for CD23 and CD21 on 
their cell surface [15]. In contrast to FoBs, murine MZBs are fairly non-circulating and reside 
in the marginal zone of the spleen[14]. MZBs are considered to be innate-like B cells and 
their localization in the spleen provides access to blood-borne pathogens, enabling them to 
mount rapidly a T-independent response [14][15][17][18]. MZBs are characterized by 
expression of high levels of CD21 and CD1d [14][15]. These markers are important for the 
effector function of MZBs. While CD21 can help the MZBs to mediate the transport of 
immune complexes to the B cell follicles, the high levels of CD1d permits MZBs to present 
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lipid antigens to natural killer T cells (NKT) [14][15]. MZBs are thought to be a vital source 
of lipid specific antibodies [14][15]. 
Lastly, murine B1 cells are also considered to be innate-like B cells, due to their effector 
functions. Unlike the B2 cells, they derive primarily from the fetal liver and occupy mainly 
the pleural and peritoneal cavities [14][17]. However, they can also be encountered in 
secondary lymphoid organs (e.g. spleen) and mucosal sites [14][17]. B1 cells can traffic and 
home to these sites continuously, and this migration is believed to be through the omentum 
and CXC-chemokine ligand 13 (CXCL13) dependent [14][19]. Moreover, B1 cells renewal 
has been suggested to take place in the spleen. This was proposed due to splenectomized 
mice experiments, which resulted in depletion of the B1 cells in the peritoneum, but not of 
the B2 cells[19][20]. Phenotypically, they are characterized by being CD19
high
, B220
low
, 
CD43+, CD23- and IgM
high
. B1 cells can be further divided into B1a and B1b by the 
expression of the surface marker CD5 on the B1a cells[19]. Functionally, B1 cells are easily 
activated and the main producers of natural antibodies. Highly crossreative, these antibodies 
are present in steady state and are important in host defense against pathogens by direct 
neutralization [19][21]. In this regard, MZBs also contribute to the pool of natural 
antibodies[18]. Giving a rapid and early immune response, B1 cells can differentiate into IgM 
secreting short-lived plasma cells, but also switch into IgA secreting cells in a T cell 
independent manner[14][17].  
Besides these B cells, we can also have other subsets depending on their different effector 
functions. Examples include B regulatory cells capable of secreting the cytokine IL-10 (B 
regulatory cells, Breg)[22] and the innate response activator (IRA) B cells responsible for 
producing granulocyte-macrophage colony stimulating factor (GM-CSF)[23][24]. 
 
1.2.2 B cell activation  
 
Activation of B cells has a central role for the generation of plasma cells and memory cells, 
which are important for host defense and ultimately a hallmark for humoral activity. Their 
activation, depending on the nature of the antigen and T cell help, can be divided into T cell 
independent (TI) and T cell dependent (TD) activation [1]. As the name indicates, TI 
responses do not require further signaling from T cells and can be subdivided into TI type I or 
type II. Whereas in TI type I responses B cells activation occurs through TLR signaling 
independently of BCR engagement, in type II responses it requires BCR antigen binding, 
specifically the crosslinking of multiples BCRs to an antigen with similar antigenic sites. 
Antigens such as LPS or bacterial DNA are a typical TI type I antigens, while long 
polysaccharides with highly repetitive binding sites are examples of TI type II antigens. In 
general, TI B cell activation is characterized by being a rapid response and resulting in the 
generation of low affinity antibodies. Additionally, TI responses might require a second 
signal from other immune cells besides T cells, such as NK cells, which can contribute for 
secretion of cytokines. As mentioned above, innate-like B cells are more likely to respond to 
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TI antigens and rapidly differentiate into short-lived plasma cells and memory cells in 
extrafollicular areas [14][25].  
Contrary to TI responses, TD B cell activation is reliant on BCR ligation to protein antigens 
and T cell help. Normally, TD antigens are recognized by FoBs and upon binding to the 
BCR, the antigens get endocytosed, degraded into peptides and presented on MHC class II 
molecules on the surface of these B cells. Alongside, activated B cells upregulate C-C 
chemokine receptor type 7, allowing them to migrate to T-B cell border and meet cognate T 
cells. Here, T cells recognizing the antigen-MHC complex presented on B cells, will provide 
the needed signals for B cell proliferation and differentiation. T cell help comprises of co-
stimulatory molecules (e.g. CD40L) and cytokines (e.g. interleukin -4 (IL-4) and IL-21) [1]. 
At this point, activated B cells can enter into two different pathways, named extrafollicular or 
follicular pathway. In the extrafollicular pathway, B cells can develop into short-lived plasma 
cells and early-memory B cells outside lymphoid follicles [26]. In the follicular pathway, 
some activated B cells will upregulate the transcription factor B cell lymphoma 6 (Bcl6) and 
return to the follicles to form GC B cells, ultimately resulting in the formation and selection 
of high affinity antibodies [26]. GCs are lymphoid microstructures found in secondary 
lymphoid organs, formed at T-B borders [27]. In the GC, B cells will induce the expression 
of activation-induced cytidine deaminase (AID), an enzyme vital for somatic hypermutation 
(SHM) and class switch recombination (CSR) [28]. On one hand, SHM results in enhanced 
antibody affinity due to the introduction of random point mutations in the antigen-binding site 
of the BCR by AID [27][29]. On the other hand, CSR results in isotype switching of the 
BCR, enabling for different effector functions of antibodies without altering their antigen 
specificity [29]. Within the GC, B cells receive support from specialized CD4+ T cells, 
named T follicular helper cells (Tfh), by the secretion of cytokines (especially IL-21) and 
costimulatory molecules [30]. Tfh are essential for the formation and maintenance of GCs, 
sustaining extensive B cell proliferation, SHM and CSR [30]. Similarly, follicular dendritic 
cells (FDCs) facilitate these processes and present complement-fixed antigens on their cell 
surface to B cells, allowing the selection of high affinity BCRs [31]. Importantly, FDCs are 
stromal cells and not DCs, and they are found in B cell follicles. Finally, B cells that undergo 
GC formation will be selected for their high affinity to the antigen and differentiate into 
plasma cells or long-lived memory B cells [26][27].  B cells that fail this selection process 
will undertake apoptosis and be phagocyte by macrophages [27][32].   
 
1.2.3 B cell effector functions 
 
B cells are normally associated with production of antibodies, but also are able to secrete 
cytokines and can present antigens to T cells (Figure 1). Briefly, B cells when activated are 
capable of differentiating into antibody secreting cells. Antibodies, also called 
immunoglobulins (Ig), are an important effector function of B cells. Structurally, they consist 
of two identical light chains and two identical heavy chains, which are associated to each 
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other by disulfide bonds to form a “Y” shape [26]. Functionally, there are two main regions 
in an antibody, the variable or the N-terminus region and the constant or C-terminus region. 
While the variable region of the heavy and light chains is responsible for binding to the 
antigen, the constant region of the heavy chains is essential for the effector functions of the 
antibody. Based on the C-terminus regions of the heavy chains, five isotypes of antibodies 
can be defined, IgM, IgD, IgG, IgA and IgE [1][26].  Depending on the isotype and binding 
affinities, different effector functions can be exerted [1][26]. The main ones are: 1) 
neutralization of pathogens or toxins, which prevent the infection of healthy cells; 2) 
opsonization, which is a process where the targets are tagged with antibodies to facilitate their 
phagocytosis; 3) complement activation (IgM is a good activator of the classical pathway of 
complement system); and 4) antibody-dependent cell-mediated cytotoxicity (ADCC), where 
for example NK cells bind to IgG coated cells and provoke the lysis of the targets [1][26]. 
Ultimately, antibodies provide us with immunity against infections, but if self-reactive can 
also participate in disease pathologies (e.g. autoimmune diseases). 
Another function of B cells is their ability to present antigens to T cells. As any other APC, B 
cells express the molecule MHC class II on their surface. Stepwise, once the BCR binds to 
the antigen on B cells, it gets internalized, processed and presented on a MHC class II 
molecule. This allows B cells to present antigen peptides to CD4
+
 T cells [26]. Though, DCs 
are more effective APCs than B cells, it has been demonstrated that B cells are also important 
for proliferation and differentiation of T cells [33][34][35][36], especially when the antigen is 
limited [37][38][39]. Additionally, B cells can act as APCs to cognate CD4+ T cells with 
high efficiency, in order to gain help for production of high affinity antibodies[36]. Similarly 
to DCs, B cells also present co-stimulatory molecules, such as CD80, CD86 and CD40, 
which are important for the activation and proliferation of T cells [26][38].  
Finally, B cells can act as immunomodulators by the secretion of cytokines. Long known for 
this ability, only recently has this topic been closely studied, motivated mostly by B cell 
depletion experiments with rituximab (anti-CD20 antibody) for treatment of autoimmune 
diseases. Interestingly, many patients that received rituximab showed improved symptoms of 
the disease without a corresponding decrease in autoantibodies levels in the serum [40][41]. 
Taken together, this suggests that B cells might have a role in the disease progression in an 
antibody-independent manner [41]. The cellular origins of these cytokine-producing B cells is 
still in debate, but B cells upon TLR binding, T cell priming or both are able to secrete 
cytokines and chemokines [38][40][41]. Lund and Harris were the first to divide B cells 
depending on their cytokine profile and effect on the T helper cells (Th) polarization [42]. 
Therefore, B effector (Be) 1 would produce Th1 like cytokines, including interferon-γ (IFNγ), 
IL-12p40 and tumor necrosis factor (TNF), while Be2 would secrete Th2 like cytokines, IL-2, 
IL-4, IL-13, IL-6 and TNF [41][42]. Moreover, in later studies, it was found that Be1 cells 
IFNγ secretion was dependent on the activation of IFNγ receptor and the T-box transcription 
factor, T-bet, on B cells [41][43]. In contrast, Be2 “commitment” was observed to be 
controlled by the activation of IL-4 receptor  on B cells and Th2 cells [41][44]. Hence, B 
cells are able to produce a broad variety of cytokines, not only the Be1 and Be2, but also pro-
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inflammatory cytokines IL-1, IFN- and lymphotoxin (LT) [40][45]; the hematopoietic 
growth factor GM-CSF [23][24]; and C-C chemokines ligand 5 (CCL5) and CCL7 
[40][46][47]. Functionally more studies are needed, but it has been reported that TNF 
promotes the expansion of CD4+ T cells [48] and differentiation of Th1 together with CCL3 
[45][49], in different infection models. IFNγ is suggested to promote Th1 responses and 
macrophage activation [40][45][50]. And LTβ is responsible for the development of 
secondary and tertiary lymphoid organs [40][41][45]. Additionally, B regulatory cells are 
considered a cytokine-producing B cell subset of its own. Responsible for producing anti-
inflammatory cytokine IL-10, they have a regulatory function in the immune system [51]. 
Until now, it was reported different subsets within the Breg population: T2-MZP (marginal 
zone progenitors) [52], MZBs [53], B10 cells (CD5+ CD1d
high
) [54], plasma cells [55] and 
plasmablasts [56]. 
 
 
 
 
 
 
Figure 1. Depiction of  B cell effector functions; including antibody production by plasma cells (P); 
antigen presentation to T cells (T) and respective interactions; and examples of cytokine secretion, such 
IL-6, LT and IFNγ and possible target cells (T cells, dendritic cells (DC) and macrophages (M)) and  
the immunosuppressive IL-10 and IL-35 (mentioned section 1.4.1) blocking T cells.  
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1.3 MACROPHAGES 
 
Macrophages are specialized myeloid immune cells characterized by their ability to 
phagocytose foreign material, debris and dead cells. They were first described by Ilya 
Metchnikoff, the father of cellular immunology, almost 200 years ago, referring to them as 
“the big eaters” from the Greek makros `large´ and phagein `eat´ [57]. Since then, 
macrophages were found to participate in diverse functions in the organism and to have an 
essential role in innate and adaptive immune system. This is enabled by their remarkable 
plasticity, which allows macrophages to respond to different environment cues. In this 
section, I will go more in depth on their origins, populations and functions. 
 
1.3.1 Origin and classifications 
 
In adult mammals, macrophages are found all over the body, where they display cellular and 
functional diversity [58]. Originally, tissue-resident macrophages were thought to 
differentiate from circulating monocytes, which originate from hematopoietic stem cells 
precursors in the bone marrow [58]. This concept arises from the initial macrophage 
classification, where they are considered part of the mononuclear phagocyte system (MPS) 
[59]. A system that encompasses all phagocytic cells with hematopoietic cell linage derived 
from progenitor cells in the bone marrow [60]. However, reports from monocytopenic human 
patients and mouse models showed practically unaffected tissue-resident macrophages 
populations [59][61]. Such observations suggested a different origin for these cells during 
ontogeny and with the support of fate-mapping studies the concept of MPS was revised 
[59][58].  Now, it is accepted that there are three different lineages for macrophages in the 
mouse: yolk sac-derived and fetal liver-derived during embryogenesis and bone marrow 
HSC-derived in adulthood [58][62]. During embryogenesis, yolk sac progenitors give rise to 
most of the tissue-resident macrophages of the skin, brain, lung, liver, pancreas and spleen. 
They are defined as F4/80 bright and are characterized as long-lived and self-renewed, 
persisting into adulthood [58][59].  In parallel, the fetal-liver has been shown to contribute to 
this group of macrophages. In tissues, such as the lung, it was found that macrophages can 
have a chimeric origin from yolk sac and fetal liver [58]. During adulthood, bone marrow 
HSC-derived circulating Ly6C+ monocytes can differentiate into short-lived and non-self-
renewing F4/80low tissue-resident macrophages [58][59]. They can be found in peripheral 
tissue with ongoing homeostatic inflammatory conditions, for example the intestine and 
mammary gland [59][58]. In sum, tissue-resident macrophages from healthy tissue are 
normally establish prenatally, while macrophages associated with homeostatic inflammation 
are typically derived from tissue-infiltrating monocytes developed in adulthood [59].   
Tissue-resident macrophages have distinct gene expression and epigenetic profiles. They are 
integral components of the host tissues and can take different forms.  For example, in the 
spleen, there exist marginal zone macrophages, metallophilic macrophages (MMM) and red 
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pulp macrophages; in the peritoneum, the peritoneal macrophages; in the liver, kupffer cells; 
in the brain, microglia and in the bone, osteoclasts [59].  
Macrophages can also be classified based on their activation or “polarization” state in 
response to different cues under non-homeostatic conditions [62]. Traditionally, macrophages 
were simply categorized into two extreme states of activation, named as classical activated 
macrophages (M1) and alternatively activated (M2) macrophages [63]. These terms reflected 
the different effects of specific cytokines in inducing distinct Th immune responses. 
Specifically, whereas the inflammatory cytokine IFNγ was able to polarize macrophages to 
M1 phenotype and participate in Th1 cell responses, the M2-polarized macrophages were 
induced by IL-4 and/or IL-13, cytokines characteristic of a Th2 driven immune response 
[63][64][65][66]. However, this binary classification was not able to reflect the complexity 
and diversity of macrophages found in vivo, lacking granularity [64][67]. Thereby, a more 
complete view/classification was set to account for transcriptional, morphological and 
secretory profile changes together with their functions. Thinking in a more continuous 
spectrum of macrophages instead of a linear one, macrophages were then grouped depending 
on their functions, namely host defense, wound healing and immune regulation [68]. This 
was depicted as a color wheel, where the three primary colors represented the three main 
macrophages and the merging colors/secondary colors signified the different-shades of 
macrophages yet to be identified, sharing functions with two out of the three types of 
macrophages [68].  The M1 or classically activated macrophages are responsible for the host 
defense and are induced mainly by IFNγ and TLR stimulation (e.g. LPS, but also TNF 
secreted by other immune cells. This signal combination results in a macrophage able to 
produce high amounts of pro-inflammatory cytokines IL-1β, IL-6 and IL-23 and chemokines 
CCL2, CCL15, CXCL9 and CXCL10 [68]. M1 macrophages are also characterized by the 
upregulation of Nos2, responsible for encoding the enzyme inducible nitric oxide synthase 
(iNOS), which stimulates the synthesis of nitric oxide (NO) from L-arginine [66]. Together 
with increased production of NO, M1 macrophages increase their production of reactive 
oxygen species (ROS), resulting in potent cytotoxic activity against pathogens [69]. In 
general, classically activated macrophages cytokine profile amplifies the Th1 immune 
response. Moreover, IFNγ and TNF increase the expression of MHC class II and co-
stimulatory molecules (e.g. CD86) on M1 macrophages [1]. These features augment the 
capacity of antigen presentation by macrophages and further support T cells responses.     
On the contrary, M2 wound healing macrophages are polarized by anti-inflammatory 
cytokines IL-4 and IL-13 [66]. These cytokines are produced by basophils, mast cells and 
other granulocytes and important drivers of Th2 immune responses.  Interestingly, both 
cytokines can also be secreted by Th2 T cells, which in turn support the development and 
maintenance of these type macrophages [67][70]. M2 wound healing macrophages are 
characterized by the upregulation of arginase-1 (Arg1), responsible for encoding the protein 
arginase, an enzyme involved in the production of extracellular matrix, important for wound 
healing [67]. Other markers such as Fizz1 (Retnla), Ym1 (Chi3l3), IL-4 receptor (IL4ra) and 
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chemokines such as CCL17, CCL18 and CCL22 help to further define these macrophages 
[67][68][71]. 
Lastly, regulatory macrophages are characterized by a strong secretion of the 
immunosuppressive cytokine IL-10 and abrogation of IL-12 [68]. Several factors have been 
implicated with the differentiation of regulatory macrophages, including TLR agonists, 
immune complexes, apoptotic cells, prostaglandins, dopamine, histamine and the IL-10 itself 
[68]. Different combinations of these stimuli will give rise to different regulatory 
subpopulations of macrophages. Nevertheless, all regulatory macrophages are characterized 
by the necessity of two stimuli for their anti-inflammatory activity (first signal being for 
example immune complexes or apoptotic cells and the second signal a TLR ligand) and the 
downregulation of IL-12 followed by the upregulation of IL-10. These macrophages are 
important inhibitors of inflammation and differ from wound healing macrophages, since do 
not contribute for the assembly of extracellular matrix [68].  
In summary, all different macrophage polarization states can be influenced by both innate and 
adaptive signals and if not properly regulated can lead to potential participation in disease. Of 
note, it is important to mention that classification of macrophages is still not fully known and 
accepted as they are very plastic cells. 
 
1.3.2 Macrophage functions 
 
The heterogeneity of macrophage populations in responding to different environmental 
stimuli allows them to participating in a wide range of functions. Their most known ability is 
phagocytosis, the capacity to uptake and clear off foreign bodies as well as intracellular 
endogenous debris. Macrophages can recognize these pathogens and modified self-ligands by 
a family of receptors named PPRs, as mentioned in the first chapter. They can be found 
membrane-bound and in the cytosol at intracellular compartments. There are different classes 
of PPRs, including TLRs, NOD-like receptors (NLR), C-type lectin receptors and scavenger 
receptors [1].  In particular, TLRs can bind to wide range of PAMPs and can be expressed in 
the cell membrane and intracellular compartments. For instance, extracellular TLR4 binds to 
LPS and intracellular TLR9 can sense methylated DNA. Likewise, scavenger receptors can 
bind to different ligands of pathogens, apoptotic cells and modified lipids and as the name 
suggests, scavenge and phagocyte these threats [72][73]. Scavenger receptors are a broad 
family with at least eight classes (called A-H). For the purpose of this thesis, I will focus on 
one type of scavenger receptor named macrophage receptor with collagenous structure 
(MARCO). This class A scavenger receptor is mainly found on splenic marginal zone 
macrophages, peritoneal macrophages and the medullary cords of lymph nodes [74]. In the 
spleen, they strategically locate in the marginal zone (MZ) where the blood flows slowly, 
granting them access to blood-borne antigens [75]. Moreover, they interact with MZBs that 
are in close proximity and MARCO expression has been associated with retaining these cells 
in the marginal zone [76]. MARCO structurally has a short intracellular domain without any 
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signaling motif, suggesting that it needs a signaling partner for downstream signaling [74]. 
However, the molecular mechanisms mediating MARCO signal transduction remain 
unknown. Nevertheless, MARCO has an important role in inflammation and apoptotic cell 
clearance [75][77][78]. It is important to mention that PPRs are differentially expressed in 
different polarized macrophages, participating also in wound healing and immune regulation.  
Macrophages not only participate in immunosurveillance, but they can also contribute to 
other physiological functions. For example, microglia have been shown to participate in brain 
development, more specifically in a process called synaptic pruning, consisting in the 
clearance of defective or immature neuronal synapses [58][79][80]. Similarly, macrophages 
in the mammary gland have been observed to play a role in the growth and branching of the 
ductal structure during pregnancy. Additionally, osteoclasts (tissue-resident macrophages of 
the bone) have been shown to influence bone generation through the secretion of molecules 
promoting or inhibiting bone formation, such as cardiotrophin-1 or semaphoring 4D 
respectively [79][81]. More recently, macrophages have been linked to maintain metabolic 
homeostasis in the adipose tissue, pancreas and liver. Regarding the adipose-tissue 
macrophages, in healthy conditions, they are able to sustain insulin sensitivity in adipocytes 
partly through the secretion and action of IL-10 [58][79]. In the liver, kupffer cells are 
involved in cholesterol recycling in the plasma and express high-density lipoprotein receptors 
(HDL-R) as well as low-density lipoprotein receptors (LDL-R) [59][82]. Since macrophages 
have wide range of functions, it is natural that they play an important part in disease 
initiation, promotion and progression. This will be discussed in the chapter 1.4.2 in regards of 
cancer. 
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Figure 2. Representation of the tumor microenvironment, including the tumor cells (hypoxic or not), 
blood vessels, lymphatic vessels, adipocytes, pericytes, cancer-associated fibroblasts (CAFs), 
mesenchymal stem cells and immune cells (T and B cells, dendritic cells, macrophages, NK and NKT 
cells and neutrophils). 
1.4 THE TUMOR MICROENVIRONMENT 
 
Cancer is a complex disease where transformed cells attain throughout time 
hyperproliferation, invasiveness and survival abilities [83]. However, a tumor is not only 
comprised of cancer cells. Tumor microenvironment contains a wide range of cells, such as 
pericytes, cancer-associated fibroblasts, adipocytes, endothelial cells and immune cells 
(Figure 2) [83][84].  All these cells together create an intricate network that supports tumor 
growth and metastasis. Within the tumor infiltrating immune cells, we can find T and B cells, 
NK cells, tumor-associated macrophages (TAMs), myeloid-derived suppressor cells 
(MDSCs), dendritic cells, neutrophils and eosinophils [84].  
 
 
 
 
 
 
 
 
 
 
Crosstalk between tumor, immune cells and different environment cues is a complex process 
that will dictate the fate for anti-tumor or pro-tumor immunity. In 1957, Thomas and Burnet 
postulated that the immune system can recognize and eliminate transformed cells, in their 
immunosurveillance theory [85][86][87][88]. It was only until decades later, with the 
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improvement of genetic mouse models for cancer and blocking monoclonal antibody 
technology that this concept was accepted. Currently, it is known and has been demonstrated 
that the immune system plays a dual role in cancer development. In a dynamic process, the 
immune system not only can protect the host against tumor growth, but also can actively 
participate in promoting its progression. This gave rise to a new concept named cancer 
immunoediting, which consists in three steps: elimination, equilibrium and escape[89].  
Briefly, the elimination phase, as described before, encompasses the concept of 
immunosurveillance. This is followed by an equilibrium stage, where there is a dynamic 
balance between immune cells and the remaining tumor cells that have survived the 
elimination phase. The mechanisms of this step are still not fully understood, nevertheless it 
is recognized that some tumor cells acquire genetic and epigenetic changes during this phase, 
which in turn will enable them resistant to immune recognition [86][90].  Additionally, this 
phase is also characterized by a balance between pro-tumor (e.g. IL-10) and anti-tumor (e.g. 
IL-12) cytokines [90]. Immune escape represents the final phase of immunoediting, where 
selected tumor cells with immune escape advantage take over and begin to expand 
progressively and uncontrollably. The tumor can avoid immune recognition through different 
mechanisms, such as loss of tumor antigens, downregulation of the antigen presentation 
molecule MHC class I and the upregulation of inhibitory surface proteins (e.g.  PD-L1) 
[85][86].  As a consequence, this will lead to absence of T cell recognition of the tumor and 
inhibition of T cell activation. Moreover, tumor can establish an immunosuppressive 
microenvironment through the production of IL-6, tumor necrosis factor beta (TGFβ), CSF1 
and vascular endothelial growth factor (VEGF) for example, which in turn will skew the 
immune cells towards a pro-tumor phenotype [86]. Increasing evidence on immune escape 
controls were recently recognized by being part of the ´Hallmarks of Cancer´, along with 
tumor-promoting inflammation, which is intricately connected with immune system and has 
been largely associated with tumorigenesis [86][91]. For this thesis, I will only focus on two 
types of immune cells within the tumor microenvironment: B cells and tumor-associated 
macrophages.  
 
1.4.1 B cells in solid cancers  
 
The tumor immunology field has been so far focused on the study of T cells and TAMs, 
mostly because they are predominant tumor-infiltrating immune cells [92]. However, B cells 
are too known to infiltrate human tumors, such as in melanoma, breast, colorectal, prostate, 
ovarian and small lung cancer [93][94][95][96][97]. Mostly from correlative studies, tumor-
infiltrating B cells have been suggested to have either a supportive or suppressive role in 
tumorigenesis. In 1970s, tumor-infiltrating B cells (TIBs) were for the first time reported to 
be protumorogenic. By using anti-IgM to deplete B cells in a murine tumor model, they 
found slower tumor growth and a decrease rate of spontaneous metastasis in the lung [98]. In 
later studies, the formation of IgG immune complexes was correlated with poor prognosis 
[99][100][101][102][103]. Mechanistically, these can deposit in the tumor stroma, resulting 
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in the recruitment of immunosuppressive myeloid cells via the engagement Fcγ receptors 
(FcγR) [101][102]. With the discovery of Bregs, it was found that TIBs could exert their 
tumor immunosuppressive function by the production of IL-10 and TGFβ. More specifically, 
Bregs can differentiate naïve CD4
+
 T cells into T regulatory cells, which can lead to cancer 
metastasis [104]. Recently, IL-35 secreting TIBs were associated to facilitate tumor cell 
proliferation in pancreatic cancer [105]. Additionally, TIBs might have a potential role in 
cancer therapy efficiency. Shalapour et al. showed that tumor-infiltrating plasma cells, 
expressing IgA and producing IL-10, can negatively modulate the chemotherapy response in 
three different mouse models for prostate cancer. These plasma cells , when present in the 
tumor, inhibited the cytotoxic function of T cells induced by the chemotherapy [106]. 
In contrast to this tumor supportive role, B cells might act as APCs to autologous T cells, 
promoting T cell proliferation and hence, affecting the tumor progression [107]. Moreover, 
CD20+ B cells were detected to be in close proximity to CD8+ T cells in the tumor stroma, 
which correlated to favorable prognosis in ovarian cancer [108]. Studies in a melanoma 
mouse model further demonstrated the importance of B cells in the CD4+ and CD8+ T cells 
responses towards the tumor [109]. In this study, depletion of B cells led to impaired T cell 
response and ultimately, increase in tumor volume and metastasis [109]. Additional evidence 
that TIBs might play a role in anti-tumor immunity comes from their ability to secrete 
lymphotoxin. This cytokine, as mentioned in 1.2.3 subchapter, facilitates the development of 
secondary and tertiary lymphoid structures (TLS) and in the tumor, enables the formation of 
ectopic TLS [92][102][103]. Likewise, in human cancers,  the number of TLS is associated 
with a positive outcome [92][102][110].  
 
1.4.2 Tumor associated macrophages 
 
Macrophages are found to infiltrate a wide range of tumors, representing in some cases up to 
50% of the total tumor mass in both mouse and human cancers [111][112][113]. Notably, 
TAMs are normally correlated with poor prognosis and can participate in all stages of 
carcinogenesis, from initiation to metastasis [114][115][116][117]. In response to an 
inflammatory tumor microenvironment, TAMs are recruited to the tumor and start to secrete 
IL-6, IFNγ and TNF, further supporting inflammation. This step is thought to be crucial to 
sustain chronic inflammation in the tumor microenvironment, creating a mutagenic milieu 
and thereby supporting tumor initiation and promotion [114].  Once the cancer is established, 
TAMs are educated to develop a more pro-tumoral phenotype [114][118][119]. This is 
accompanied by a shift in T cell responses, from a Th1 to Th2 type immunity, resulting in 
polarization of macrophages to M2-like. Cytokines such IL-4 and IL-13 are known to 
promote this M2-like phenotype, as well as increase production of growth factors by the 
tumor, including colony stimulating factor-1 (CSF1) and GM-CSF [114]. One of the 
mechanisms where TAMs can promote tumor progression is by supporting an 
immunosuppressive environment through secretion of cytokines and chemokines. For 
  15 
instance, TAMs can induce CD4+ T cells to become T regulatory cells (Tregs) thought the 
secretion of IL-10 and TGFβ. Both cytokines were found to induce this T cell phenotype by 
upregulating the transcription factor Foxp3 in CD4+ T cells [114][120][121]. Additionally, 
IL-10 and TGFβ inhibit cytotoxic T cells as well as Th1 and Th2 CD4+ helper functions 
[114][122][123]. TAMs are also able to recruit Tregs to the tumor microenvironment, 
indirectly suppressing effector cells.  Chemokines CCL20 and CCL22 synthetized by TAMs 
recruit CCR6+ Tregs in human ovarian adenocarcinoma and CCR4+ Tregs in colorectal 
cancer, respectively [124][125]. Additionally, TAMs can secrete the enzyme arginase 1 and 
metabolize L-arginine, which plays an important role in the re-expression of CD3ζ chain after 
downregulation of TCR upon antigen stimulation [114][126][127]. Expression of cell surface 
markers, CTLA-4 (Cytotoxic- T lymphocyte antigen 4), PD-1 (Programmed cell death 
protein 1) and PD-L1 (Programmed cell death-ligand 1) on macrophages can also contribute 
to the inhibition of cytotoxic T cell functions when engaging with their respective ligands 
(CD80/CD86; PD-L1/PD-L2 and PD-1, respectively) [114]. In the particular case of PD-L1, 
TAMs have been shown to upregulate this molecule as consequence of hypoxia-inducible 
factor-1 alpha (HIF-1) signaling in hypoxic regions of the tumor [128]. 
Angiogenesis, or formation of new blood vessels, is a necessary step for tumor growth [91]. 
Stepwise, for the creation of new vessels, the recruitment of endothelial cells needs to be 
preceded by the destruction of the basement membrane and extracellular matrix (ECM) 
[111]. This process is enabled by TAMs by the production of proteolytic enzymes that 
degrade ECM, such as matrix metalloproteases-2 and -9 (MMP-2 and MMP-9) and the 
release of pro-angiogenic factors, including TNF, TGFβ, vascular endothelial growth factor 
(VEGF) and pallet-derived growth factor (PDGF) [111]. VEGF besides increasing vascular 
permeability can also promote migration of TAMs to the tumor and in hypoxia conditions it 
is upregulated by macrophages along with the expression of angiopoietin 2 receptor (Tie2) 
[111][129][130]. 
Lastly, TAMs participate in tumor cell invasion and metastasis in different tumors [116]. 
Tumor cells can secrete CCL2 and recruit CCR2+ Ly6C+ monocytes to the site, where they 
differentiate in metastasis-associated macrophages (MAMs) [131]. Phenotypically, these 
macrophages are characterized by the expression of CCR2, VEGF receptor and F4/80 and 
promote cell extravasation partly via expression of VEGF [114][131]. When depleted this 
MAM population, results in inhibition of metastatic seeding and consequent growth 
[111][131][132].  
It is important to mention that some TAMs (proinflammatory M1-like) can also have a 
tumoricidal function. They can identify altered glycosylation patterns of cell surface 
molecules in tumor cells via binding of lectin-like receptors and lyse tumor cells by 
generation of ROS and NO [111]. Moreover, they can inhibit tumor metastasis directly and 
indirectly through the production of certain factors, including interferons and platelet factor 4 
(PF4 or CXCL4) [111][133]. However, the tumor microenvironment promotes a more 
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immunosuppressive phenotype as described before, which can be further stimulated through 
the release of TGFβ and prostaglandin E2 by tumor cells [111].  
In summary, TAMs secrete a variety of cytokines, chemokines, enzymes, growth factors and 
express specific cell surface molecules that directly or indirectly support tumor initiation, 
promotion, progression and metastasis. Nevertheless, further investigation is needed in 
regards to the different subpopulations of TAMs and their distribution in human cancers.  
 
1.5 CANCER IMMUNOTHERAPY  
 
Cancer immunotherapy it is based on the principle that enhancing the immune response and 
restoring its reactivity may neutralize or eliminate cancer [134]. This is achieved by using 
components or mechanisms to stimulate the immune system [134]. Cancer immunotherapy 
can be further divided into active and passive. Active immunotherapy attempts to induce a 
specific and long-lasting anti-tumor immune response [135]. In other words, vaccination is 
used as an active method to stimulate the immune system. Tumor vaccination can go from 
using tumor-associated proteins and peptides as immunogens to dendritic cell vaccination 
[134][135]. In contrast, passive immunotherapy does not provoke a memory response and 
uses monoclonal antibodies or the transfer of donor cytotoxic T cells to directly target the 
cancer cells or activate the host adaptive immune system [135]. One type of monoclonal 
antibodies that has changed the current cancer treatments is checkpoint blockade antibodies 
[136]. This strategy aims to reverse the immunosuppression present in the tumor 
microenvironment by blocking the inhibitory receptors present on T cells and consequently, 
stimulate them to exert their anti-tumor functions [137]. This method has shown success in 
the clinic, as anti-CTLA-4, anti-PD-1 and anti-PD-L1 therapies are FDA approved  [137]. 
CTLA-4 is inhibitory receptor that is expressed transiently on T cells and constitutively on T 
regulatory cells [137]. T cells, when they get activated by CD28 binding to CD80 or CD86 on 
APCs, CTLA-4 gets expressed on the cell surface, competing for the same ligands. CTLA-4 
engagement results in T cell activation dampening and acts as a control mechanism of the 
immune system [1][137]. However, when the same happens in a cancer setting, T cells 
cannot perform their anti-tumor activity and therefore, the need of CTLA-4 blockade 
antibodies. In 1996, James P. Allison was able to demonstrate this in a murine model, where 
treated mice led to the rejection of the tumors[138]. PD-1 is also an inhibitory receptor 
expressed on T cells and similarly to CTLA-4, suppresses the T cell function[137]. It binds to 
PD-L1 and PD-L2, which are expressed on the surface of APCs and tumor cells. In this case, 
cancer cells can immune escape the cytotoxic function of T cells by binding to PD-1[137].  In 
some cancers, the expression of this ligand is normally associated with poor prognosis[137]. 
Checkpoint therapies, however, can incite certain side effects connected to overall activation 
of T cells[135]. 
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2 AIMS 
 
Paper I. To investigate the role of tumor infiltrating B cells in a mouse model for melanoma 
and breast cancer 
Paper II. To study the effect of checkpoint therapies, anti-PD-1 and anti-PD-L1, on the B 
cell responses towards melanoma antigens in a murine model and human cancer 
Paper III. To investigate the scavenger receptor MARCO expression on TAMs and inhibit 
tumor progression by reprogramming immunosuppressive TAMs using a monoclonal 
antibody against MARCO 
Paper IV. To examine the expression of MARCO on TAMs in non-small cell lung cancer 
 
 
  21 
3 RESULTS AND DISCUSSION 
 
3.1 THE TUMOR MICROENVIRONMENT INDUCES INNATE CYTOKINE 
PRODUCING B CELLS (PAPER I) 
 
The study of the tumor microenvironment, especially the crosstalk between cancer cells and 
immune cells, has enabled us to better understanding of tumor initiation, progression, 
metastasis and resistance to therapy. Nevertheless, many questions continue to be 
unanswered, including which B cells subpopulations infiltrate the tumor and their respective 
function. This immune cell type has long been known for their role in humoral immunity, but 
they are also important antigen-presenting cells and immunomodulators through cytokine 
production. Recent studies have found that TIBs are part of the tumor milieu and they may 
play either a supportive or suppressive function in tumor growth. In paper I, we sought to 
clarify the role of TIBs, specially the phenotype and functions, in two mouse models for 
melanoma and breast cancer. 
Using a B16 mouse model modified to express membrane-bound ovalbumin (B16 mOVA), 
we confirmed by immunofluorescence the presence of B220+ TIB cells nearby the tumor 
blood/lymphatic vessels and/or the tumor capsule. Notably, these regions were enriched by 
infiltrating CD3+ T cells and NK1.1 NK cells. The presence of B cells in the tumor milieu 
was further proven using flow cytometry. Here, we could detect CD19+ TIB cells and two 
major TIB subpopulations identified by CD5 expression or lack of it on the cell surface. 
Similarly, an orthotopic model for breast cancer (EO77.1) showed the same TIB 
subpopulations within the tumor.  Expression of CD5 is normally associated to a specific 
subset of B cells in mice, named B1a cells [139]. They are considered to be innate-like B 
cells and can mount immune responses in a T independent manner, thus contributing to the 
first line of the host defense. The presence of the surface marker CD5 on CD19+ TIBs then 
suggested that these cells might be innate-like B1. Using a genetic mouse model lacking B1 
B cells (Bumble mice) [140], we could detect a significant reduction of CD5+ TIBs in the 
B16 mOVA model when compared to littermate controls. Strengthening this finding, the B1 
B cell surface marker CD43 was markedly expressed on CD5+ TIB subpopulation [141]. 
Taken together, it indicates that CD5+ B cell subset infiltrating the tumor might be an innate-
like B1 cell.  
We further assessed the phenotype of these two TIB subpopulations by using flow cytometry. 
In both mouse models, we observed higher expression levels of the activation markers CD69 
and CD86 on CD5+ TIB cells compared to their CD5- counterparts. Functionally, we looked 
into the ability of TIBs to secrete cytokines in the tumor microenvironment. Notably, no IL-
10 expression was detected in neither of TIB subpopulations. Instead, CD19+ TIBs secreted 
proinflammatory cytokines TNF and IFNγ, specially the CD5+ fraction. Altogether, CD5+ 
TIBs have a more activated and a proinflammatory profile compared to the CD5- TIB 
faction. 
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To explore if the tumor milieu had any impact on the cytokine production of TIBs, we in 
vitro stimulated naïve peritoneal B cells with tumor conditioned medium (‘T.C.M.’) from 
B16 mOVA. This ´T.C.M.´ was collected after ex vivo culture of 10 to 14 days bulk tumors, 
thus mimicking the microenvironment that B cells might encounter when infiltrating the 
tumor. This had especially a focus on the molecules produced by the cells within this milieu. 
In line with the in vivo data, we detected that ´T.C.M.´ conditioned peritoneal CD5+ B cells 
acquired a proinflammatory phenotype. More specifically, these B cells secreted more TNF 
and IFNγ and less IL-10 when compared to control (medium cultured B cells), particularly 
when further stimulated with LPS.  
In the particular case of IFNγ, it is known that two pathways are responsible for the secretion 
of this cytokine by B cells, a T cell dependent and independent way. Whereas, for the T cell 
dependent way, IFNγ secretion by CD4+ T cells directly promotes its production in B cells 
[42][43], for the independent pathway, it requires normally the cytokines IL-12 and IL-18 
[43][142]. In vivo, we observed very few IFNγ+ CD4+ T cells infiltrating the B16 mOVA 
tumors, suggesting that these cells might not be the responsible inducers of IFNγ secretion in 
CD5+ TIB cells. For the independent pathway, we could detect the presence of IL-12 in 
´T.C.M.´, but undetectable IL-18 protein levels. Focusing then on the IL-12, isolated ex vivo 
tumor cells and the cell line itself were proven to be not responsible for its production. TAMs 
activated in a M1-like state are known to produce IL-12 in these conditions [143][144]. In 
vitro cultured F4/80+ TAMs isolated from the tumor were capable of secreting IL-12 and in 
similar levels to those detected in ´T.C.M.´. Therefore, these results show that TAMs might 
be accountable for the IFNγ production in CD5+ TIB cells. Nevertheless, we cannot entirely 
exclude the participation of CD4+ T cells.   
Next, we examined the potential effect of TIBs on other immune cells in the tumor 
microenvironment. Using anti-CD20 antibody in vivo, we observed a complete depletion of B 
cells in the B16 mOVA tumors. This was accompanied by a significant decrease in IFNγ+ 
CD8+ T cells and CD3- NK1.1+ NK cells. We further examined these results in an in vitro 
co-culture system. Notably, CD8+ T cells when co-cultured with ´T.C.M.´ conditioned B 
cells showed a decrease in IFNγ+ CD8+T cells, which revealed to have an exhausted 
phenotype, with higher expression of LAG3 and Tim-3 compared to control. In contrast, 
tumor conditioned B cells were found to increase IFNγ+ and CD107+ cytotoxic NK cells. 
Thus, our data suggest that intratumoral B cells affect both cytotoxic T and NK cells, leading 
to exhaustion of CD8+T cells and an increase in IFNγ+ NK cells.  
Additionally, B cell depletion allowed us to observe a possible effect on the tumor growth. 
However, no significant difference in tumor volume was observed during the experimental 
time. Interestingly, when using the Bumble mice, which lack B 1 cells, we could detect an 
increased tumor growth compared to littermate controls. Moreover, we could show a negative 
correlation between CD5+TIBs and tumor volume. Altogether, this might indicate a possible 
CD5+TIB subpopulation with antitumoral activities. 
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Finally, we confirmed the presence of CD19+ TIBs in the tumor of human breast cancer 
tissue by flow cytometry. Along with the mouse in vivo data, we could identify TIBs 
expressing either CD43 or CD5 and secreting the proinflammatory cytokines TNF and IFNγ. 
Using The Cancer Immunome Atlas, we further observed that melanoma and breast cancer 
patients had better overall survival when high number of activating B cells were present in 
the tumor.  
In summary, we could identify an innate-like B1 cells infiltrating the tumor of murine 
melanoma and breast cancer models. This subpopulation was characterized by having an 
activated phenotype and a proinflammatory profile, which was further associated with a 
direct effect of the tumor milieu. Likewise, human breast cancer was also found to be 
infiltrated by similar B cells and thus, giving us a better understanding of the several B cell 
subpopulations infiltrating the tumor and their possible effector functions. 
 
3.2 B CELL RESPONSES TO CHECKPOINT THERAPY IN MELANOMA 
(PAPER II) 
 
The overall clinical success of immune checkpoint therapies brought a promising cure for a 
wide range of cancers. Nevertheless, within the treated patients there is still quite 
heterogeneity in the outcome, ranging from complete remission to non-responders and in 
some cases, accompanied with immune-related adverse events (IRAEs). A recent study on 
patients receiving combination checkpoint therapy reported the importance of changes in 
circulating B cells subsets in predicting IRAEs, acting as biomarkers [145]. This study was 
the first of its own nature and in line with our paper II that tries to answer how the B cell 
responses are affected by the checkpoint therapies, in particular the anti-PD-1 and anti-PD-
L1. 
Using the same mouse melanoma model as in paper I, we treated tumor bearing mice with the 
checkpoint inhibitors, anti-PD-1 and anti-PD-L1, and PBS as control. As expected, after three 
treatment injections a significant reduction of the tumor size was observed, being nearly gone 
in some cases. Interestingly, we could detect an increase in OVA specific IgG antibodies, on 
days 14 and 21, in serum of mice treated with checkpoint therapies. This was accompanied 
by no significant differences in GC B cells in both spleen and draining lymph nodes (dLN). 
Notably, depending on the treatment given, differences in the IgG subclasses were observed 
in the serum of tumor bearing mice. Whereas for anti-PD-1 treatment, we could notice an 
increase in OVA specific IgG1 and IgG3; for anti-PD-L1, anti-OVA IgG2b and IgG2c levels 
were significantly increased compared to control. It is important to mention that this effect 
was specific to the tumor, since OVA immunization in Alum followed by checkpoint therapy 
did not result in a change of IgG subclasses in the serum.  
In an attempt to explain the differences in antibody responses observed in the serum of 
treated mice, we examined the Tfh and T follicular regulatory (Tfreg) populations present in 
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the secondary lymphoid organs. Tfh cells are important CD4+ T cells present in the B cell 
follicles and responsible to deliver survival signals to GC B cells and are connected to B cell 
SHM and CSR [30][146]. In the opposite side, CD4+ Tfreg cells, characterized by FOXP3 
expression, were observed to suppress Tfh and GC B cell proliferation [147][148]. In this 
study, Tfh were identified by the double expression of surface CXCR5 and PD-1; and Tfreg 
with the additional expression of the intracellular transcription factor FOXP3. Notably, we 
could observe, in dLN of tumor-bearing mice treated with anti-PD-L1, a significant increase 
of Tfh cells when compared to control. Likewise, splenic Tfh were markedly increased along 
with decrease in splenic Tfreg cells. However, for anti-PD-1 treatment no significant changes 
were observed for both T follicular cell subpopulations in dLN, with the exception of an 
increase in splenic Tfreg cells. For anti-PD-1 therapy, we were hypothesizing greater 
variations on these cells, since Tfh and Tfregs are characterized by a high expression of PD-1 
and thus, being natural targets for this treatment.  Nevertheless, a further characterization is 
needed of these cells to clarify the present results as well as a closer examination of the GC 
kinetics.  
Class switching is also greatly influenced by the cytokine milieu present in an immune 
response [149]. Thus, we explored the potential role of cytokines present in the serum of 
treated mice. So far, we could identify increased levels of IFNγ in mice receiving anti-PD-1 
compared to control. This result partially explain the differences in IgG subclasses found in 
anti-PD-1 treated mice, as previously reported, IFNγ alone is known to increase IgG3 levels, 
but also decrease IgG1 [149][150]. As such, a more detailed cytokine profiling in the serum 
of these mice is needed to fully comprehend these results. 
Next, we investigated if variation in melanoma specific antibodies was also detected in the 
serum of patients undergoing anti-PD-1 therapy. Notably, only three patients had an increase 
in IgG antibodies towards the neo-antigen New York-esophageal squamous cell carcinoma-1 
(NY-ESO-1), when comparing before and after treatment. Moreover, we were not able to 
detect any differences in IgG levels for melanoma-associated antigen recognized by T cells-1 
(MART-1) as well as for changes in the BCR of circulating B cells. Altogether, these results 
did not translate what was observed in the mouse setting for the melanoma model. Further 
experiments are required to fully clarify if there is no difference in B cell responses in a 
human context. Nevertheless, it is noteworthy to mention the distinct antibody response 
found in a melanoma mouse model when using different immune checkpoint therapies.   
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3.3 REPROGRAMMING TUMOR ASSOCIATED MACROPHAGES BY 
ANTIBODY TARGETING INHIBITS CANCER PROGRESSION AND 
METASTASIS (PAPER III) 
 
TAMs are heterogeneous myeloid population present in the tumor microenvironment capable 
of a wide range of functions, from tumor initiation to metastasis. In paper III, we aimed to 
investigate MARCO expression on TAMs and to potentially reprogram them to inhibit cancer 
progression. 
The scavenger receptor MARCO has a restricted expression on certain tissue-resident 
macrophages and on activated DCs [74][151]. To test whether MARCO was also present on 
TAMs, we screened three different cancer mouse models using immunofluorescence, namely 
mammary carcinoma (4T1), melanoma (B16) and colon carcinoma (MC38). Here, we found 
MARCO to be co-expressed on F4/80+ macrophages close to the tumor capsule. Importantly, 
no other myeloid or lymphocytes expressed MARCO in the tumor microenvironment, 
indicating its unique expression on TAMs infiltrating B16 tumors. Furthermore, MARCO 
expression was not present in all F4/80+ TAMs, suggesting that this receptor defines a 
distinct subset of TAMs. Using flow cytometry and qPCR, we could show that MARCO was 
expressed on a specific subpopulation of TAMs phenotypically characterized by CD11b+ 
Ly6G- Ly6C
low
 and MHCII
low
. This subset is considered to have a M2-like polarization, 
which we observed by the gene expression of Cx3cr1, Arg1 and Retnla, along with MARCO 
presence. Additionally, this subpopulation of TAMs exhibited low expression of M1 markers 
(H2-Ab1 and Nos2) confirming MARCO expression on macrophages with a M2-like gene 
signature in the tumor microenvironment. 
Next, we explored the possible factors behind the upregulation of MARCO on this subset of 
TAMs. Using bone-marrow-derived macrophages (BMDMs) in vitro polarization system, we 
observed upregulation of MARCO on M2-polarized and tumor supernatant stimulated 
macrophages. Taking into account that cytokines such as IL-10 and TGFβ are associated with 
an immunosuppressive environment in the tumor and can promote M2-like polarization, we 
hypothesized that these cytokines might drive MARCO expression. Stimulation of BMDMs 
with either IL-10 or TGFβ resulted in upregulation of MARCO on these cells. Nevertheless, 
we failed to further prove it by using blocking antibodies against either cytokines in vitro, 
possible due to the participation of other factor in the tumor supernatant.  
Since MARCO has a restricted expression on immunosuppressive TAMs, it gave us the 
opportunity to use a monoclonal antibody against MARCO as a potential target for cancer 
immunotherapy. Notably, both melanoma and breast cancer models showed a decrease in 
tumor growth when treated with anti-MARCO antibody.  In the particular case of breast 
cancer, this was observed together with a significant reduction in metastasis. Moreover, flow 
cytometry analysis on 4T1 tumors revealed a shift from M2- to M1-like TAMs in the tumor 
microenvironment. Likewise, gene expression of TAMs from the melanoma model showed 
an upregulation of M1 related genes (Il1b) and a downregulation of Il10, a M2 marker. We 
could not identify any additional differences in other tumor infiltrating immune cells, with the 
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exception of an increase in CD4+/Tregs ratio and OVA-specific CD8+ T cells in the B16 
tumors. Mechanistically, anti-MARCO effect might be attributed to the inhibitory function of 
FcγRIIb, since its effect was not observed in deficient mice for this receptor. 
In the melanoma model, combination of anti-MARCO treatment with anti-CTLA-4 immune 
checkpoint antibody also proved to further decrease tumor growth and increased survival 
compared to anti-CTLA-4 alone. Similarly, we could observe an increase of efficiency of 
anti-MARCO in combination with anti-CTLA-4 when treating MC38 tumors. Thus, these 
results show the potential effect of anti-MARCO on current immunotherapies. 
Finally, immunofluorescence stainings on human breast cancer and metastatic melanoma 
showed the presence of MARCO on a subset of CD68+ TAMs together with M2 marker 
CD163. Moreover, TCGA and KI/Clinseq datasets on human breast cancer revealed high 
expression of MARCO in the triple negative subgroup of patients compared to LumA, LumB 
and Her2 positive subgroups. This subset of patients are normally diagnosed with poor 
prognosis and have very limited treatment options, thus anti-MARCO could be a potential 
treatment for these patients.  
In summary, scavenger receptor MARCO defines a subset of TAMs with an 
immunosuppressive phenotype and when targeted with a monoclonal antibody results in a 
decrease tumor growth and metastasis. Moreover, anti-MARCO in combination with 
checkpoint therapy anti-CTLA-4 antibody enhances its effect on decrease tumor growth and 
increased survival. Clinical data additionally confirmed the presence of MARCO on 
protumor TAMs in human breast cancer and metastatic melanoma. Altogether, repolarization 
of TAMs with anti-MARCO gives light to a novel and promising approach for cancer 
treatments.   
 
3.4 EXPRESSION OF SCAVENGER RECEPTOR MARCO DEFINES A 
TARGETABLE TUMOR-ASSOCIATED MACROPHAGE SUBSET IN NON-
SMALL CELL LUNG CANCER (PAPER IV) 
 
As described on Paper III, MARCO was found to be expressed on TAMs and when targeted 
with a monoclonal antibody was observed to suppress tumor growth and metastasis. In Paper 
IV, we aimed to characterize MARCO expression on TAMs in non-small cell lung cancer 
(NSCLC) cohort and its relation to other macrophage markers. 
To investigate the presence of TAMs in NSCLC patients, tissue microarrays (TMA) were 
stained for macrophage pan marker CD68 and protumor tumor markers CD163, macrophage 
scavenger receptor 1 (MSR1) and MARCO [152][153]. Notably, we could observe a patient 
heterogeneity when it came to the infiltration of macrophages in the different compartments 
of the tumor, namely lumen, stroma and tumor. Macrophage density differed from low to 
high depending on the case and additionally, patients with squamous cell carcinomas had in 
average a higher density of CD68+ TAMs compared to adenocarcinomas. Interestingly, we 
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could observe a strong correlation between mean and distribution of CD163 scores to the 
ones for CD68. This indicates that most of TAMs present in the tumor have an 
immunosuppressive phenotype. Moreover, MARCO expression on TAMs was lower 
compared to other markers, suggesting that MARCO defines a distinct subpopulation of 
TAMs in NSCLC. Likewise, we could identify similar pattern for MSR1, although not has 
pronounced as MARCO.  
To further investigate this MARCO+ TAM subpopulation, we used immunohistochemistry 
and immunofluorescence analysis on TAMs. We could detect a fraction of MARCO+ 
macrophages co-staining with CD68 and CD163, demonstrating the immunosuppressive 
nature of MARCO+ TAMs. Similarly to before, different patients had a large variation on the 
density of MARCO+ macrophages infiltrating the tumor. Notably, in several patients 
MARCO+ TAMs tended to situate at the tumor-stroma border, in close proximity to tumor 
islets.  
Given this localization and the possibility of targeting this immunosuppressive barrier with 
current immunotherapy, we extended the characterization of MARCO+ TAMs 
subpopulation. The checkpoint inhibitor PD-L1 was found to be co-express with MARCO on 
CD68+TAMs located in and around the tumor cell islets. Gene expression analysis confirmed 
the positive correlation between MARCO and PD-L1, but also to other checkpoint genes, 
such as PD-1, CTLA-4 and V-domain Ig suppressor of T cell activation (VISTA). 
Additionally, clinical data on the adenocarcinoma patients showed a tendency for worse 
overall survival when tumors were highly infiltrated by macrophages, though it was not 
significant. 
Overall, this study follows up on the findings from paper III and reports a distinct TAM 
subpopulation infiltrating NSCLC based on MARCO expression. Moreover, their localization 
in the tumor, close to cell nests, and co-expression with PD-L1, makes MARCO+ TAMs an 
interesting target for cancer immunotherapy. 
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
This thesis brings insight on our understanding of two major immune cells in the tumor 
microenvironment. More specifically, it focuses on: the role of B cells in the tumor 
microenvironment and their importance in checkpoint therapies; and the detection of an 
immunosuppressive subpopulation of TAMs in different mouse and human cancers, with the 
possibility of modulating them with a monoclonal antibody to an anti-tumor phenotype. The 
main findings are the following: 
 
I. Tumor-infiltrating innate-like B1 cells have a proinflammatory cytokine profile in the 
tumor microenvironment of melanoma and breast cancer. 
Paper I contributed for our general understanding of the role of B cells in the tumor 
microenvironment. We revealed that mouse models for melanoma and breast cancer are 
infiltrated by a heterogeneous B cell population, which are phenotypically and functionally 
different. This suggested the importance for future studies to differentiate the CD19 positive 
B cell population into different subsets (as done with T cells) and not representing them 
simply as bulk. In particular, we demonstrated the presence of a tumor-induced 
proinflammatory CD5+ TIB subset, with an activated state, in both mouse and human 
cancers. And although, we could not conclude about their active participation in tumor 
initiation and progression, we did observe a reverse correlation between frequency of CD5+ 
TIBs and tumor volume.  Moreover, mice lacking CD5+ B cells showed increased tumor 
growth compared to littermate controls. Altogether, this data suggested an anti-tumor 
phenotype of CD5+ TIBs, but further experiments are required. Additionally, we observed 
the potential effect of TIBs on cytotoxic T and NK cells, leading to exhaustion and activation 
respectively. To conclude this paper, we should further explore the different TIB subsets 
responsible for this result and the mechanisms behind it. Moreover, it would be interesting to 
know the origin of these B cells in the tumor microenvironment and expand this research to 
other tumors. Finally, the increase overall survival of melanoma and breast cancer patients 
with high infiltration of activated B cells makes these cells potential predictive biomarkers.  
 
II. Melanoma specific antibody responses depend on the immune checkpoint therapy given. 
In similar line with Paper I, we attempted to extend our knowledge of checkpoint therapies, 
namely anti-PD-1 and anti-PD-L1, in a B cell response perspective. Our major finding was 
the preferential tumor specific IgG subclasses depending on the treatment given to the tumor 
bearing mice. And although, we could not observe a substantial increase in tumor specific 
IgG serum levels in melanoma patients receiving anti-PD-1, it does not exclude the 
importance of this finding in the melanoma mouse model. In fact, it raises important 
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questions, such as: “How different IgG isotypes play a role in anti-tumor immunity?”; “Does 
this effect occur in other tumor models?” and “Does it have a predictive value in response to 
therapy?”. Answering these questions are a good basis for future experiments, but for this 
paper we still need to explore more the cytokine influence on B cell antibody responses as 
well as the germinal center response kinetics. For the human melanoma cohort, it would be 
also worth to further investigate the different IgG subclasses in serum of patients and the T 
cell responses towards the melanoma antigens reported in this paper. 
 
III. Targeting MARCO positive tumor associated macrophages with a monoclonal antibody 
results in hinder tumor growth and metastasis.  
In paper II, we found a novel marker defining a subpopulation of immunosuppressive TAMs 
in mouse and human cancers. This was especially important, since MARCO was observed to 
be highly expressed in the triple negative breast cancer patients, a very aggressive tumor with 
poor prognosis. Further investigations are needed, but MARCO could potentially be a novel 
biomarker for this subset of breast cancer. Moreover, it would be interesting to expand this 
research to various types of cancers. We could also find a new strategy for cancer 
immunotherapy by modulating TAMs polarization with a monoclonal antibody. So far, this 
approach has only been focused and successful by blocking CSF1, an important growth factor 
to sustain M2-like TAMs in the tumor microenvironment. For the future, we still need to 
further clarify the mechanism by which anti-MARCO exerts its effector function in the 
tumor. Moreover, we should further characterize the TAM polarization towards M1, when 
targeted with anti-MARCO antibody (e.g. metabolic changes). In addition, it would be 
interesting to identify the set of factors, such as cytokines, responsible for inducing MARCO 
expression on TAMs, since IL-10 and TGFβ blocking experiments did not result in a 
downregulation of this receptor. 
 
IV. MARCO is a novel marker for a subset of immunosuppressive TAMs in non-small cell 
lung cancer.  
In paper IV, we mainly found that MARCO is expressed in a subset of immunosuppressive 
TAMs in NSCLC patients, strategically localized between the stroma and tumor cell islets. 
This immunosuppressive barrier makes these cells a possible target for cancer 
immunotherapy. Additionally, it could improve tumor progression blockade effect for 
NSCLC in combination with current checkpoint treatments, since MARCO+TAMs express 
also surface PD-L1. For future experiments, an effort to know the localization of MARCO+ 
TAMs in regards to other tumor -infiltrating immune cells should be performed. As 
MARCO+ TAMs are found at the stoma-tumor border, it would be interesting to observe if 
these cells hinder the entrance of cytotoxic lymphocytes into the tumor nests. Finally, we 
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should explore the function of MARCO+ TAMs in human cancers to know how they exert 
their protumor functions.  
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